Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.
about
A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden deathMyomegalin is a novel A-kinase anchoring protein involved in the phosphorylation of cardiac myosin binding protein CMuscle LIM protein interacts with cofilin 2 and regulates F-actin dynamics in cardiac and skeletal muscleDouble heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathyGenetic counselling for hypertrophic cardiomyopathy: are we ready for it?Genetic Misdiagnoses and the Potential for Health DisparitiesA Review of the Giant Protein Titin in Clinical Molecular Diagnostics of CardiomyopathiesQRS fragmentation: its role in sherlocking the arrhythmogenic heartCardiac sympathetic activity in hypertrophic cardiomyopathy and Tako-tsubo cardiomyopathyCardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem CellsQuality Control and Reproducibility in M-Mode, Two-Dimensional, and Speckle Tracking Echocardiography Acquisition and Analysis: The CARDIA Study, Year 25 Examination Experience.The cell biology of disease: cellular mechanisms of cardiomyopathy.The Role of Genetic Testing in the Identification of Young Athletes with Inherited Primitive Cardiac Disorders at Risk of Exercise Sudden DeathRecent advances in genetic testing and counseling for inherited arrhythmiasClinical and Mechanistic Insights Into the Genetics of CardiomyopathyMolecular mechanisms of cardiomyopathy phenotypes associated with myosin light chain mutationsMutations in filamin C cause a new form of familial hypertrophic cardiomyopathySystematic analysis of the regulatory and essential myosin light chain genes: genetic variants and mutations in hypertrophic cardiomyopathyCompound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defectsThe ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathyMybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in miceIncreased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in miceA mutation in TNNC1-encoded cardiac troponin C, TNNC1-A31S, predisposes to hypertrophic cardiomyopathy and ventricular fibrillationAbnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cellsFounder mutations in hypertrophic cardiomyopathy patients in the NetherlandsMolecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin CGenotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethoninPerturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutationsRescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in miceMutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humansMYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correctionCombinatorial effects of double cardiomyopathy mutant alleles in rodent myocytes: a predictive cellular model of myofilament dysregulation in diseaseCardiomyopathy in α-kinase 3 (ALPK3)-deficient miceHuman-based approaches to pharmacology and cardiology: an interdisciplinary and intersectorial workshop.Structure and function of cardiac troponin C (TNNC1): Implications for heart failure, cardiomyopathies, and troponin modulating drugsMyocardial structural alteration and systolic dysfunction in preclinical hypertrophic cardiomyopathy mutation carriersUse of Theranostic Strategies in Myocardial Cavitation-Enabled TherapyThe A31P missense mutation in cardiac myosin binding protein C alters protein structure but does not cause haploinsufficiency.Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation.Insights into human beta-cardiac myosin function from single molecule and single cell studies.
P2860
Q21261488-6ED3302D-DDBD-4F8C-BAF5-0C356E35A602Q24302222-FB1DB4A0-C803-4773-A01B-A22D8336D62DQ24645285-3B93CCE9-3FD7-453E-8E22-93ED1312F22DQ24681653-853EDC55-9AEF-411E-B856-BCCDD2A14CE3Q24792466-3AB67F06-F5F0-449C-B0A9-97D1FA1BDFB5Q26316693-B727DB5A-1201-4E82-8D19-781A3CA53630Q26738818-61255FBD-9464-4A7C-B4CE-0A16FE594BEAQ26741049-FE439708-CFB9-4AA9-B94D-AE57D82D17D9Q26784294-6448A43C-BCA4-4BC1-A71F-0CA14F954D06Q26798131-10A4A98E-D0C7-4D2D-B349-6371987C856CQ27313525-1EFEBB26-3C83-40EC-924D-792A1CAF4325Q27686758-59E87EA6-1F12-4C4B-B672-6AE111925079Q28066330-684C3F45-B837-4CE3-821C-9FA2A5332F6CQ28074154-4DB37DFF-F3A2-4F6D-BA39-50ABD706C4F8Q28075470-DEA8E79E-ACED-405B-8CF1-6BB73F519272Q28088824-72891F1C-DA97-45C6-AB32-A6DCDA5DF83DQ28115580-EE95EE19-86E3-4B39-A53A-1A569D382B67Q28211536-8491C851-5B63-4F1F-9FB3-8BFF8268BD21Q28250082-FED3530F-EE06-4A44-A2E7-4F2DB3C75D41Q28252486-0ADDCE21-8C6B-49BA-9A16-9E5A094AD7ACQ28253008-57E004B3-EFAF-46A1-ACA9-5807C63C9759Q28263306-672C933C-4EE4-41B9-AE72-73A93BB0B6BBQ28271478-2FF6F5CB-FE39-4E4F-AB6E-21A5ACF82FC1Q28282675-6F229C61-8478-4CC7-8BAB-3501A78A28E8Q28283579-C93EADDA-A341-4FAC-BBF6-1D1CD994AAA6Q28284750-D2DDF528-481B-4984-97E2-9EEA9EBDA3C4Q28286640-0C1CAF2D-49EE-4AF3-B55B-39AD8F0AE78DQ28287468-9C4F7871-9DA6-44C7-A9DB-845B210DC2BCQ28291547-A5F364FC-6FD1-403D-BDEB-B285EE0E0A3BQ28302847-77339032-45D3-4933-83B6-4B23A6CF95FFQ28304022-09DF2D78-4E52-48F0-9E0C-85A79725038BQ28472836-BD4F242E-1637-4B27-99EE-97E86C167113Q28589708-AB2EB9F0-D530-48EC-A09C-5E412DA60493Q28596483-45729DE8-08D7-4E41-A6A8-04FA96331893Q28607749-FD291243-091A-4838-B637-DF25EC48508BQ28730121-35AA685C-7304-4F0B-BC57-C9C10FC4FA8FQ30380567-F616B80F-C52A-46D1-A546-EEA9A05218C9Q30383609-448E8868-AD8E-460E-8C2F-727685C55A27Q30388756-E797334D-5CF1-437F-995C-9B043E195179Q30390486-36E51785-C1BC-4D50-A413-3E425D0FF695
P2860
Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.
description
1995 nî lūn-bûn
@nan
1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Prevalence of hypertrophic car ...... Development in (Young) Adults.
@ast
Prevalence of hypertrophic car ...... Development in (Young) Adults.
@en
Prevalence of hypertrophic car ...... ary Artery Risk Development in
@nl
type
label
Prevalence of hypertrophic car ...... Development in (Young) Adults.
@ast
Prevalence of hypertrophic car ...... Development in (Young) Adults.
@en
Prevalence of hypertrophic car ...... ary Artery Risk Development in
@nl
prefLabel
Prevalence of hypertrophic car ...... Development in (Young) Adults.
@ast
Prevalence of hypertrophic car ...... Development in (Young) Adults.
@en
Prevalence of hypertrophic car ...... ary Artery Risk Development in
@nl
P2093
P356
P1433
P1476
Prevalence of hypertrophic car ...... Development in (Young) Adults.
@en
P2093
P304
P356
10.1161/01.CIR.92.4.785
P407
P577
1995-08-01T00:00:00Z